Results of a 2nd comparative analyze were documented by Flinn et al. This is the phase III randomized Intergroup demo evaluating FC regimen compared to FAMP on your own in 278 clients receiving their 1st chemotherapy regimen for B-CLL. Dosages of FC plan have been similar to the first examine. https://friedrichb322nyj5.yourkwikimage.com/user